Idiopathic pulmonary fibrosis

This study tests whether metformin, a standard diabetes medicine, can slow the worsening of idiopathic pulmonary fibrosis (IPF), a serious lung disease. About 400 high-risk patients will receive either metformin or a placebo. The goal is to see if metformin can delay death, hospi…

This study looks at the long-term safety of a drug called admilparant in people with pulmonary fibrosis (lung scarring). About 2,277 adults who finished earlier studies will take the drug and be monitored for side effects. The goal is to see if the drug is safe to use over time, …

This phase 2 trial tests whether an experimental drug called HSK50042 can improve lung function in adults with idiopathic pulmonary fibrosis (IPF), a chronic condition that causes lung scarring and breathing difficulties. Participants take HSK50042 or a placebo once daily for 26 …

This phase 3 trial is testing whether an experimental drug called AK3280 can slow the decline in lung function for people with idiopathic pulmonary fibrosis (IPF), a condition that causes progressive lung scarring. About 263 adults aged 40 and older with IPF will receive either A…

This Phase II trial tests whether a combination of therapeutic plasma exchange (filtering the blood), rituximab (a drug that targets certain immune cells), and intravenous immunoglobulin (IVIg) can slow lung decline in people with progressive idiopathic pulmonary fibrosis (IPF). …

This study will test if a smart pill bottle cap, called FORTISKAP™, helps people with serious lung diseases like pulmonary fibrosis, sarcoidosis, and pulmonary hypertension take their oral medications more consistently. About 100 participants will either use the smart cap or rece…

This study tests an experimental tablet called SYH2059 in 156 adults with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing harder. Participants will receive either the drug or a placebo to see if it can slow the decline in lung function. The…

This early-stage trial tests a new tablet called HW241045 in 102 healthy volunteers to see if it is safe and how the body processes it. The drug is being developed for idiopathic pulmonary fibrosis, a lung-scarring disease. The study is randomized, double-blind, and placebo-contr…

This phase 2 trial tests whether adding dextromethorphan to the standard drug nidanib helps people with idiopathic pulmonary fibrosis (IPF). About 60 adults aged 40 and older will take either the combo or nidanib alone for 12 weeks. The main goal is to see if lung function (FVC) …

This study tests a new tablet, HSK44459, for people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. About 420 adults aged 40 and older will receive either the drug or a placebo for 52 weeks. The main goal is to see if the drug he…

This early study tests whether inhaling tiny particles from stem cells (extracellular vesicles) is safe for people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. Nine adults with mild-to-moderate IPF will inhale the treatment tw…

This early-phase trial will test a stem cell product called REGEND007 in 12 people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. The stem cells are given through an IV, and the main goal is to check safety and find the right do…

This early-stage trial tests a new cell therapy for people with end-stage idiopathic pulmonary fibrosis (IPF), a disease that causes severe lung scarring and breathing failure. The therapy uses specially engineered immune cells to target and reduce scarring in the lungs. The stud…

This study looks at whether routine blood tests can help predict how patients with a sudden worsening of idiopathic pulmonary fibrosis (IPF) will fare. Researchers will track blood cell ratios and oxygen levels in hospitalized patients over two weeks. The goal is to see if change…

People with interstitial lung disease (ILD) can suddenly get much worse, but it is hard to tell if the cause is a lung flare-up or a blood clot in the lungs (pulmonary embolism). This observational study will follow 70 adults with ILD who come to the hospital with worsening breat…

This study uses web-based interviews to explore how adults in Japan with pulmonary fibrosis decide whether to continue or stop antifibrotic therapy after experiencing side effects. Researchers aim to understand the personal and psychological factors behind these decisions. The fi…

This study is testing whether an integrated precision medicine platform can improve how doctors diagnose and manage chronic inflammatory lung diseases like COPD and idiopathic pulmonary fibrosis. Researchers will collect blood and saliva samples for biomarker analysis, monitor in…

This phase 1 trial tests a new investigational drug, SCB0020160, for the first time in humans. Healthy adult men aged 18 to 65 receive either the drug or a placebo to evaluate safety, tolerability, and how the drug moves through the body. The study also looks at whether food affe…

This study tests whether people with fibrotic interstitial lung disease can use home monitoring devices—like a spirometer, pulse oximeter, and scale—to help detect serious lung events such as flare-ups or hospitalizations. About 200 participants will use these devices connected t…

This early-stage study tests a new inhaled drug called RC010 in 42 healthy adults in China. The main goal is to check if it is safe and how the body processes it. This drug is being developed for a serious lung condition called idiopathic pulmonary fibrosis (IPF), but this study …

This early-stage study tests a new drug, HW252001, in 98 healthy adults aged 18 to 55. The goal is to check the drug's safety and how the body processes it, not to treat any disease. Participants will receive either the drug or a placebo, and researchers will monitor for side eff…

This observational study will collect data from 1000 people with idiopathic pulmonary fibrosis (IPF) across multiple Italian centers. Researchers will use machine learning to build a model that predicts disease progression, acute flare-ups, and response to treatment. The goal is …

This study tests whether motivational interviewing, delivered through video calls and online platforms, can improve self-care in 124 adults with idiopathic pulmonary fibrosis (IPF). Participants will be randomly assigned to receive the counseling or usual care. Researchers will m…

This study will observe 2,864 people with idiopathic pulmonary fibrosis (IPF) to learn how the disease changes over time and how it relates to traditional Chinese medicine syndromes. Researchers will track lung function, exercise ability, quality of life, and other health markers…

This study will follow 1,000 people with idiopathic pulmonary fibrosis (IPF), a serious lung disease that causes scarring and breathing problems. Researchers will compare those who take traditional Chinese medicine (TCM) for at least three months a year to those who do not. The g…